JGC
MIST icon

J. Goldman & Co’s Milestone Pharmaceuticals MIST Stock Holding History

J. Goldman & Co’s Portfolio MIST Stock Details MIST Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-100,283
Closed -$581K – 468
2021
Q1 		$581K Sell
100,283
-5,235
-5% -$38.3K 0.02% 344
2020
Q4 		$707K Buy
+105,518
New +$706K 0.04% 260

Other funds holding MIST

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
NHAS
Novo Holdings A/S Hellerup, Denmark $1.23B AUM 81.32% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
IC
Ikarian Capital Dallas, Texas $1.23B AUM 600.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
PVI
Pura Vida Investments New York $14.9M AUM 38.76% 1-Year Est. Return

J. Goldman & Co's MIST Position: Q2 2021 in Review

J. Goldman & Co sold out of Milestone Pharmaceuticals (MIST) in Q2 2021, closing a stake of 100,283 shares — an estimated $581K sold.

J. Goldman & Co first reported a position in MIST in Q4 2020 and held it in 2 quarters. The position peaked at $707K in Q4 2020. 28 funds tracked by Wall St. Rank hold MIST as of Q2 2021.

  • J. Goldman & Co reported no remaining Milestone Pharmaceuticals position as of Q2 2021 after selling out during the quarter.
  • J. Goldman & Co sold 100,283 Milestone Pharmaceuticals shares in Q2 2021, an estimated $581K.
  • J. Goldman & Co first reported a position in Milestone Pharmaceuticals in Q4 2020 and held it in 2 quarters.
  • J. Goldman & Co's Milestone Pharmaceuticals position peaked at $707K in Q4 2020.
  • 28 funds tracked by Wall St. Rank held Milestone Pharmaceuticals as of Q2 2021.

Based on J. Goldman & Co's 13F filing for Q2 2021, filed 16 Aug 2021.